Welcome to FASD Tasmania. Our mission is to reduce the incidence of FASD and to offer better support options and build service delivery capacity to improve the lives of those living with FASD.
We acknowledge the varied national and international sources of resources posted on this website.
FASD is estimated to affect 2.4% to 4.8% (midpoint, 3.6%) of the general population (May et al, 2014). This year, a global estimate is predicted at 119,000 children born annually with fetal alcohol exposure (Popova et al 2017).
Over 250,000 births occur each year in Australia and with 50 per cent of pregnancies proposed to be unplanned and as many as 60% of women consuming some amount of alcohol from the time of conception to confirmation of pregnancy, the risk of adverse fetal outcomes and neurodevelopmental impairment is very real. If US estimates are applied, (midpoint 3.6% of general population), more than 83,000 individuals could be affected and most will be undiagnosed. Cost has been difficult to estimate. In Canada,
The cost associated with FASD in Canada in 2013 (based on the cost drivers included in this study) totaled approximately $1.8 billion (from about $1.3 billion as the lower estimate to $2.3 billion as the upper estimate). The highest contributor to the overall FASD-attributable cost was the cost of productivity losses due to disability and premature mortality, which accounted for 42% (between $532 million and $1.2 billion) of the overall cost. The second highest contributor was the cost of corrections, accounting for 30% ($378.3 million). The third highest contributor was the cost of health care at 10% (between $128.5 and $226.3 million).
 Popova et al (2015) ‘The Burden and Economic Impact of Fetal Alcohol Spectrum Disorder in Canada.’ Feb 2015. https://www.camh.ca/en/research/news_and_publications/reports_and_books/Documents/Burden%20and%20Eco%20Costs%20FASD%20Feb%202015.pdf
 Popova S. et al. (2017) ‘Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis.’ The Lancet Global Health,